PANTOPRAZOLE SODIUM
Clinical safety rating: safe
Animal studies have demonstrated safety
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
| Metabolism | Primarily metabolized by CYP2C19 and CYP3A4. |
| Excretion | Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1% |
| Half-life | Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps |
| Protein binding | ~98% bound, primarily to albumin |
| Volume of Distribution | 0.15 L/kg; low Vd indicates limited extravascular distribution |
| Bioavailability | Oral: 77% (tablet); IV: 100% |
| Onset of Action | Oral: peak effect on gastric acid secretion in 2–4 hours; IV: within 15–30 minutes |
| Duration of Action | Acid suppression lasts up to 24 hours; maximal effect after 2–4 days of repeated dosing |
| Molecular Weight | 383.37 |
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to severe renal impairment. For patients on hemodialysis, maximum dose is 40 mg/day. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B or C: maximum dose 20 mg/day (oral or intravenous). |
| Pediatric use | Children 5 years and older: weight <40 kg: 20 mg orally once daily for 8 weeks; weight ≥40 kg: 40 mg orally once daily for 8 weeks. For intravenous use in children ≥5 years: 0.5-1 mg/kg once daily, max 40 mg/day. |
| Geriatric use | No dose adjustment generally required; consider reduced hepatic function: maximum 40 mg/day for short-term use (8 weeks) for erosive esophagitis; monitor for adverse effects. |
| 1st trimester | Human data insufficient; animal studies show no teratogenic effects. Avoid unless clearly needed. |
| 2nd trimester | Limited human data suggest low risk; use only if benefit outweighs risk. |
| 3rd trimester | Limited human data; possible risk of infant hypocalcemia if used near term. Use with caution. |
Clinical note
Can reduce absorption of drugs requiring gastric pH for absorption (eg ketoconazole) May increase risk of Clostridium difficile-associated diarrhea and bone fractures with long-term use.
| Placental transfer | Crosses placenta in animals; human data limited but likely low transfer due to molecular weight and protein binding. |
| Breastfeeding | Excreted in human milk in low concentrations; unlikely to cause adverse effects in infants. Use caution in premature infants or those with renal impairment. |
■ FDA Black Box Warning
None.
| Common Effects | Diarrhea Flatulence Headache Nausea Stomach pain Vomiting Dizziness Upper respiratory tract infection |
| Serious Effects |
Hypersensitivity to pantoprazole or any component of the formulationConcomitant administration with rilpivirine-containing products
| Precautions | Acute interstitial nephritis, Clostridium difficile-associated diarrhea, Bone fracture risk with long-term use, Hypomagnesemia, Vitamin B12 deficiency with prolonged use, Cutaneous lupus erythematosus, Possible interaction with methotrexate |
| Food/Dietary | Take pantoprazole at least 30 minutes before a meal; food delays absorption. Avoid alcohol as it may exacerbate gastric irritation. No specific dietary restrictions, but a diet low in fat and spicy foods may help manage symptoms. Do not take with high-protein meals that can reduce absorption. Avoid excessive vitamin B12 deficiency risk with long-term use; ensure adequate intake of B12 from diet or supplements. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data; increased risk of congenital malformations not observed. Avoid use in first trimester unless essential. |
| Fetal Monitoring | Monitor maternal symptoms for acid-related disorders; assess for hypomagnesemia with prolonged use; monitor infant growth and development if exposed in utero. |
| Fertility Effects | No known adverse effects on fertility in animal studies or human data. |
| Clinical Pearls | For optimal acid suppression, administer pantoprazole 30-60 minutes before a meal. Avoid concurrent use with clopidogrel due to reduced efficacy; consider a different PPI. Use with caution in hepatic impairment; no dose adjustment needed in renal impairment. Monitor for hypomagnesemia, especially in prolonged use ( >1 year) or with digoxin. IV formulations are compatible with normal saline but not with lactated Ringer's. For stress ulcer prophylaxis in critically ill patients, IV pantoprazole is an alternative to histamine-2 receptor antagonists. Discontinue if signs of acute tubulointerstitial nephritis develop. |
| Patient Advice | Take this medication exactly as prescribed, usually once daily before a meal. · Swallow the tablet whole; do not crush, chew, or split. · If using granules for oral suspension, mix with applesauce or apple juice and take immediately. · Avoid taking with other acid reducers like antacids within 30 minutes. · Report any symptoms of low magnesium such as muscle cramps, irregular heartbeat, or seizures. · Do not use for immediate relief of heartburn; it takes 1-4 days for full effect. · Complete the full course even if symptoms improve. · Inform your doctor of all medications, especially clopidogrel, warfarin, or methotrexate. · Long-term use may increase risk of bone fracture; discuss with your doctor. · Seek medical attention if you experience severe diarrhea, rash, or difficulty swallowing. |